Диссертация (1174357), страница 26
Текст из файла (страница 26)
New York,Springer-Verlag, 1995. – P. 411-437.240. Kurman, R.J. The behavior of endometrial hyperplasia. A long-term study of«untreated» hyperplasia in 170 patients / R.J. Kurman, P.F. Kaminski, H.J. Norris //Cancer. – 1985. – Vol. 56 (2). – Р. 403-412.241. Lack of estrogen receptor-α is associated with epithelial-mesenchymaltransition and PI3K alterations in endometrial carcinoma / E. Wik [et al.] // Clin. CancerRes.
– 2013. – Vol. 19 (5). – P. 1094-1105.242. Lai, C. H. The role of hormones for the treatment of endometrial hyperplasiaand endometrial cancer / C.H. Lai, H.J. Huang // Curr. Opin. Obstet. Gynecol. – 2006. –Vol. 18 (1). – P. 29-34.243. Levonorgestrel-impregnated intrauterine device astreatment for endometrialhyperplasia: a national multicentrerandomised trial / A. Orbo [et al.] // BJOG.
– 2014. –Vol. 121 (4). – P. 477-86.244. Ling, C. PRL receptor-mediated effects in female mouse adipocytes: PRLinduces suppressors of cytokine signaling expression and suppresses insulin-induced163leptin production in adipocytes in vitro / C. Ling, H. Billig // Endocrinology. – 2001. –Vol. 142 (11). – P.
480-490.245. Lipid profiles and the risk of endometrial cancer in the Swedish AMORISstudy / D. Seth [et al.] // Int. J. Mol. Epidemiol. Genet. – 2012. – Vol. 3 (2). – P. 122133.246. Lippi, U.G. Analysis of estrogen- and progesterone-receptor expression inendometrial polyps / U.G. Lippi // J. Minim. Invasive Gynecol. – 2007. – Vol. 14 (3). –P. 300-303.247.
LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: along-term comparative cohort study / I. D. Gallos [et al.] // Hum. Reprod. – 2013. – Vol.28 (11). – P. 2966-2971.248. LNG-IUDtreatmentofnon-atypicalendometrialhyperplasiainperimenopausal women: a randomized controlled trial / H.
Abu Hashim [et al.] // J.Gynecol. Oncol. – 2013. – Vol. 24 (2). – P. 128-134.249. Long-term effect of megestrol acetate in the treatment of endometrialhyperplasia / D. Gal [et al.] // Am. J. Obstet. Gynecol. – 1983. – 146 (3). – P. 316-322.250. Long-term histopathologic and morphologic changes after thermalendometrial ablation / O. Taskin [et al.] // J. Am. Assoc. Gynecol.
Laparosc. –2002. –Vol. 9 (2). – P. 186-190.251. Maggiolini, M. The unfolding stories of GPR30, a new membrane-boundestrogen receptor / M. Maggiolini, D. Picard // Endocrinol. – 2010. – Vol. 204 (2). – P.105-114.252. Management of Endometrial Precancers / C.L. Trimble [et al.] // Obstet.Gynecol. – 2012. – Vol.
120 – Р. 1160–1175.253. Management of atypical endometrial hyperplasia and endometrial carcinomausingmegestrolacetate[Electronicresource]//Modeaccess:https://clinicaltrials.gov/ct2/show/record/NCT00483327254. Maruo, T. Effects of progesterone on uterine leiomyoma growth andapoptosis / T. Maruo // Steroids. – 2000. – Vol. 65 (10-11). – P. 585-592.164255. McAveney,K.M.Prolactinreceptorexpressionduringadipocytedifferentiation of bone marrow stroma / K.M. McAveney, J.M. Gimble, L.-Y.
Yu-Lee //Endocrinology. – 1996. – Vol. 137 (12). – P. 5723–5726.256. Mechanismof estrogen action:lessonsfromthe estrogenreceptor-alpha knockout mouse / P.S. Cooke [et al.] // Biol. Reprod. – 1998. – Vol. 59 (3). – P.470-475.257. Metabolic effects associated with high-dose continuous megestrol acetateadministration in the treatment of endometrial pathology / M. Guven [et al.] // Arch.Gynecol. Obstet. – 2001.
– Vol. 265 (4). – P. 183-186.258. Mishell, D. R. Intrauterine devices: mechanism of action, safety and efficacy// Contraception. – 1998. – Vol. 58 (3 Suppl). – P. 45S-53S.259. Molecular and clinical endocrinology of the endometrium / A.M. Bamberger[et. al.] // Pathologe. – 1999. – Vol. 20 (1). – P. 50-55.260. Montgomery, B.E.
Endometrial hyperplasia: a review / B.E. Montgomery,G.S. Daum, C.J. Dunton // Obstet. Gynecol. Surv. – 2004. – Vol. 59 (5). – P. 368-78.261. Moy, B. Estrogen receptor pathway: resistance to endocrine therapy and newtherapeutic approaches / B. Moy, P.E. Goss // Clin. Cancer Res. – 2006. –Vol.12 (16). –P. 4790-4793.262. Multiple actions of steroid hormones--a focus on rapid, nongenomic effects /E. Falkenstein [et al.] // Pharmacol.
Rev. – 2000. – Vol. 52 (4). – P. 513-556.263. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias /G.L. Maxwell [et al.] // Cancer Res. 1998. – Vol. 58 (12). – 2500-2503.264. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma/ B. Dobrzycka [et al.] // Folia Histochem. Cytobiol. – 2009. – Vol.
47 (1). – P. 65-68.265. Mylonas, I. Prognostic significance and clinical importance of estrogenreceptor alpha and beta in human endometrioid adenocarcinomas / I. Mylonas // Oncol.Rep. – 2010. – Vol. 24 (2). – P. 385-393.266. Negoiţă, M. Tamoxifen and endometrial pathology. / M.
Negoiţă, C. Terinte,M.S. Mihailovici // Rev. Med. Chir. Soc. Med. Nat. Iasi. – 2010. –Vol. 114 (4). – P.1114 –1117.165267. Newell, S. Postmenopausal bleeding should be referred urgently / S. Newell,C. Overton // Practitioner. – 2012. – Vol. 256(1749). – P. 13-5, 2.268. Normal and malignant human endometrium express immunohistochemicallyestrogenreceptor alpha(ER-alpha),estrogen receptor beta(ER-beta)andprogesterone receptor (PR) / I. Mylonas [et al.] // Anticancer Res. – 2005. – Vol.
25(3A). – P. 1679-1686.269. Nuclear morphometric changes and therapy monitoring in patients withendometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel andsystemic medroxyprogesterone / A.B. Vereide [et al.] // Gynecol. Oncol. – 2003. – Vol.91 (3). – P. 526-533.270. Obesity-related hormones and endometrial cancer among postmenopausalwomen: a nested case-control study within the B~FIT cohort 112 / C.M. Dallal [et al.] //Endocr. Relat. Cancer. – 2013. – Vol. 20 (1). – P. 151-160.271. Oestrogen receptor beta expression and depth of myometrial invasion inhuman endometrial cancer / F.
Takama [et al.] // Br. J. Cancer. – 2001. – Vol. 84 (4). –P. 545-549.272. O’Hara, A.J. The genomics and genetics of endometrial cancer / A.J.O’Hara, D.W. Bell // Adv. Genomics Genet. – 2012. – Vol. 2012 (2). – P. 33-47.273. Oncologic and reproductive outcomes with progestin therapy in women withendometrial hyperplasia and grade 1 adenocarcinoma : a systematic review / C.C.Gunderson [et al.] // Gynecol.
Oncol. – 2012. – Vol. 125 (2). – P. 477-482.274. Oralmicronizedprogesterone.Bioavailabilitypharmacokinetics,pharmacological and therapeutic implications - a review / R. Sitruk-Ware [et al.] //Contraception. – 1987. – Vol. 36 (4). – P. 373-402.275. Oral progestogens vs levonorgestrel-releasing intrauterine system forendometrial hyperplasia : a systematic review and meta-analysis / I.
D. Gallos [et al.] //Am. J. Obstet. Gynecol. – 2010. – Vol. 203. – P. 547.e1-e10.276. Overexpression of p53 in the endometrial gland in postmenopausal women /Koi, C. [et al.] // Menopause. – 2015. – Vol. 22 (1). – P. 104-107.166277. Overexpression of the insulin-like growth factor I receptor and activation ofthe AKT pathway in hyperplastic endometrium / A.S. McCampbell [et al.] // Clin.Cancer Res. – 2006. – Vol. 12 (21). – P. 6373-6378.278.
Overton, C. A national survey of the complications of endometrialdestruction for menstrual disorders: the MISTLETOE study. Minimally invasivesurgical techniques--laser, endothermal or endorescetion / C. Overton, J. Hargraves, M.Maresh // British journal of obstetrics and gynaecology. –1997. – Vol. 104 (12). – 13511359.279. Overview of breast cancer collaborative stage data items-their definitions,quality, usage, and clinical implications: A review of SEER data for 2004-2010 / N.Howlader [et al.] // Cancer. – 2014. – Vol. 120. – P. 3771-3780.280.
p38 and p42/44 MAPKs differentially regulate progesterone receptor A andB isoform stabilization / J.A. Khan [et al.] // Mol. Endocrinol. – 2011. – Vol. 25 (10). –P. 1710-1724.281. p53 isoforms can regulate p53 transcriptional activity / J.C. Bourdon [et al.]// Genes Dev. – 2005. – Vol. 19 (18). – P. 2122-2137.282. p53 protein expression in nephroblastomas: a predictor of poor prognosis /D.
Govender [et al.] // Br. J. Cancer. – 1998. – Vol. 77 (2). – P. 314-318.283. Pakarinen, P. The effect of intrauterine and oral levonorgestreladministration on serum concentrations of sex hormone-binding globulin, insulin andinsulin-like growth factor binding protein-1 / P. Pakarinen, P. Lahteenmaki, E.М.Rutanen //Acta Obstet. Gynecol.
Scand. – 1999. – Vol. 78 (5). – P. 423-428.284. Palmer, J.E. Endometrial hyperplasia: Review / J.E. Palmer, B. Perunovic,J.A. Tidy // Obstet. Gynaecol. – 2008. – Vol. 10. – Р. 211-216.285. Pathologic features associated with resolution of complex atypicalhyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy / C. C.Gunderson [et al.] // Gynecol. Oncol. – 2014. – Vol. 132 (1). – P. 33-37.286. Pelkonen, R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
